Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Sareum Holdings Fundamentals

Company Name Sareum Holdings Last Updated 16 Oct 2019
Industry Health Care Sector Pharmaceuticals
Shares in Issue (m) 3,071.36 Market Cap (£m) 9.83
PE Ratio -6.40 Div per Share () 0.00
Div Yield 0.00 Div Cover 0.00
EPS -0.05 EPS Growth (%) 0.00
PEG n/a DPS Growth (%) n/a
Debt Ratio 0.00 Debt Equity Ratio 0.00
Net Gearing -62.34 Gross Gearing 11.77
Asset Equity Ratio 1.13 Cash Equity Ratio 84.00
Quick Ratio 8.28 Current Ratio 8.28
Price To Book Value 9.02 ROCE -154.13

Sareum Holdings Dividends

Type Ex-Date Pay Date Currency Net Dividend Year Total

Sareum Holdings Company Financials

Assets (£m) 2019 2018 2017
Tangible Assets 0 0 0
Intangible Assets 0 0 0
Investments 0 0 0
Total Fixed Assets 0 0 0
Stocks 0 0 0
Debtors 0 0 0
Cash & Equivalents 1 1 2
Other Assets 0 0 0
Total Assets 1 2 3
Liabilities (£m) 2019 2018 2017
Creditors within 1 year 0 0 0
Creditors after 1 year 0 0 0
Other Liabilities 0 0 0
Total Liabilities 0 0 0
Net assets 1 2 2
Equity (£m) 2019 2018 2017
Called up share capital 1 1 1
Share Premium 13 12 12
Profit / Loss -2 -2 0
Other Equity 0 0 0
Preference & Minorities 0 0 0
Total Capital Employed 1 2 2
Ratios 2019 2018 2017
Debt Ratio 0.00 0.00 0.00
Debt-to-Equity 0.00 0.00 0.00
Net Gearing -62.34 -65.64 -85.97
Gross Gearing 11.77 10.08 6.24
Assets / Equity 1.13 1.11 1.07
Cash / Equity 84.00 84.20 98.34
EPS -0.05 -0.05 0.02
Cash Flow (£m) 2019 2018 2017
Cash from operating activities -1 -2 1
Cashflow before financing -1 -2 1
Increase in Cash -0 -1 1
Income (£m) 2019 2018 2017
Turnover 0 0 0
Cost of sales 0 0 0
Gross Profit 0 0 0
Operating Profit -2 -2 0
Pre-Tax profit -2 -2 0
Profit / Loss for the year 1 1 1

Sareum Holdings Company Background

Sector Pharmaceuticals
Activities Sareum Holdings plc is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune disease. The Company aims to generates value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage. Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802). The Company is targeting first human clinical trials in each indication in 2020. Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Cancer Research UK.
Latest Interim Date 04 Mar 2019
Latest Fiscal Year End Date 15 Oct 2019

Sareum Holdings Directors

Appointed Director Position
07 Jun 2004 Dr Timothy John Mitchell Chief Executive Officer
07 Jun 2004 Dr John Charles Reader Chief Scientific Officer
17 May 2016 Dr Stephen Barry Parker Non-Executive Chairman
13 Nov 2018 Dr Michael John Owen Non-Executive Director
13 Nov 2018 Clive Hedley William Birch Non-Executive Director

Sareum Holdings Contact Details

Company Name Sareum Holdings
Company Address Unit 2A, Langford Arch, London Road, Pampisford, Cambridge CB22 3FX.
Company Telephone +44 (0)1223 497 700
Company Website http://www.sareum.co.uk/

Sareum Holdings Advisors

Auditor Name Shipleys LLP
Auditor Address 10 Orange Street, Haymarket, London WC2H 7DQ.
Auditor Website http://www.shipleys.com/
Auditor Telephone +44 (0)20 7312 0000
Registrar Name Link Asset Services
Registrar Address The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU.
Registrar Website http://www.linkassetservices.com/
Registrar Telephone 0870 162 3100
Broker Name Hybridan LLP
Broker Address 60 Lombard Street, London EC3V 9EA.
Broker Website http://www.hybridan.com/
Broker Telephone +44 (0)20 3159 5085
Adviser Name Sanlam Securities UK Limited
Adviser Address 10 King William Street, London EC4N 7TW.
Adviser Website http://www.sanlamsecuritiesuk.com/
Adviser Telephone +44 (0)207 628 2200
Solicitor Name Taylor Vinters
Solicitor Address Merlin Place, Milton Road, Cambridge CB4 0DP.
Solicitor Website http://www.taylorvinters.com/
Solicitor Telephone +44 (0)1223 423 444
Stockbroker Name n/a
Stockbroker Address n/a
Stockbroker Website n/a
Stockbroker Telephone n/a